United Therapeutics Corporation (UTHR)
USD 293.65
(-4.46%)
USD 293.65
(-4.46%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 7.16 Billion USD | 18.57% |
| 2022 | 6.04 Billion USD | 16.94% |
| 2021 | 5.16 Billion USD | 12.01% |
| 2020 | 4.61 Billion USD | 17.93% |
| 2019 | 3.91 Billion USD | 15.07% |
| 2018 | 3.4 Billion USD | 18.11% |
| 2017 | 2.87 Billion USD | 23.81% |
| 2016 | 2.32 Billion USD | 6.46% |
| 2015 | 2.18 Billion USD | 15.92% |
| 2014 | 1.88 Billion USD | -9.73% |
| 2013 | 2.08 Billion USD | 28.34% |
| 2012 | 1.62 Billion USD | 7.15% |
| 2011 | 1.51 Billion USD | 6.04% |
| 2010 | 1.43 Billion USD | 36.15% |
| 2009 | 1.05 Billion USD | 20.68% |
| 2008 | 871.31 Million USD | 48.43% |
| 2007 | 587.01 Million USD | 22.67% |
| 2006 | 478.55 Million USD | 64.22% |
| 2005 | 291.41 Million USD | 40.67% |
| 2004 | 207.15 Million USD | 15.41% |
| 2003 | 179.5 Million USD | -2.74% |
| 2002 | 184.56 Million USD | -12.99% |
| 2001 | 212.12 Million USD | -15.37% |
| 2000 | 250.64 Million USD | 318.44% |
| 1999 | 59.9 Million USD | 220.32% |
| 1998 | 18.7 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 6.49 Billion USD | -9.37% |
| 2024 Q3 | 7.12 Billion USD | 5.95% |
| 2024 Q2 | 6.72 Billion USD | 3.51% |
| 2023 Q2 | 6.68 Billion USD | 5.28% |
| 2023 Q1 | 6.34 Billion USD | 4.99% |
| 2023 FY | 7.16 Billion USD | 18.57% |
| 2023 Q4 | 7.16 Billion USD | 2.04% |
| 2023 Q3 | 7.02 Billion USD | 5.12% |
| 2022 Q3 | 5.78 Billion USD | 4.3% |
| 2022 Q4 | 6.04 Billion USD | 4.55% |
| 2022 FY | 6.04 Billion USD | 16.94% |
| 2022 Q1 | 5.35 Billion USD | 3.69% |
| 2022 Q2 | 5.54 Billion USD | 3.42% |
| 2021 Q4 | 5.16 Billion USD | 2.38% |
| 2021 FY | 5.16 Billion USD | 12.01% |
| 2021 Q1 | 4.64 Billion USD | 0.56% |
| 2021 Q2 | 4.84 Billion USD | 4.39% |
| 2021 Q3 | 5.04 Billion USD | 4.21% |
| 2020 Q4 | 4.61 Billion USD | 4.62% |
| 2020 Q3 | 4.41 Billion USD | 4.55% |
| 2020 Q1 | 4.02 Billion USD | 2.87% |
| 2020 Q2 | 4.21 Billion USD | 4.81% |
| 2020 FY | 4.61 Billion USD | 17.93% |
| 2019 Q3 | 3.99 Billion USD | 2.58% |
| 2019 Q4 | 3.91 Billion USD | -2.16% |
| 2019 FY | 3.91 Billion USD | 15.07% |
| 2019 Q1 | 3.72 Billion USD | 9.58% |
| 2019 Q2 | 3.89 Billion USD | 4.62% |
| 2018 Q2 | 3.24 Billion USD | 7.44% |
| 2018 Q1 | 3.02 Billion USD | 4.89% |
| 2018 FY | 3.4 Billion USD | 18.11% |
| 2018 Q4 | 3.4 Billion USD | -0.33% |
| 2018 Q3 | 3.41 Billion USD | 5.15% |
| 2017 Q2 | 2.69 Billion USD | 5.08% |
| 2017 FY | 2.87 Billion USD | 23.81% |
| 2017 Q1 | 2.56 Billion USD | 10.14% |
| 2017 Q3 | 2.93 Billion USD | 9.08% |
| 2017 Q4 | 2.87 Billion USD | -1.93% |
| 2016 Q1 | 2.19 Billion USD | 0.35% |
| 2016 FY | 2.32 Billion USD | 6.46% |
| 2016 Q2 | 2.2 Billion USD | 0.43% |
| 2016 Q3 | 2.26 Billion USD | 3.08% |
| 2016 Q4 | 2.32 Billion USD | 2.49% |
| 2015 Q4 | 2.18 Billion USD | 1.17% |
| 2015 Q2 | 1.73 Billion USD | -8.33% |
| 2015 Q1 | 1.89 Billion USD | 0.54% |
| 2015 FY | 2.18 Billion USD | 15.92% |
| 2015 Q3 | 2.15 Billion USD | 24.32% |
| 2014 Q4 | 1.88 Billion USD | -9.06% |
| 2014 Q3 | 2.07 Billion USD | 6.1% |
| 2014 Q2 | 1.95 Billion USD | -7.66% |
| 2014 Q1 | 2.11 Billion USD | 1.31% |
| 2014 FY | 1.88 Billion USD | -9.73% |
| 2013 Q3 | 1.92 Billion USD | 8.44% |
| 2013 FY | 2.08 Billion USD | 28.34% |
| 2013 Q4 | 2.08 Billion USD | 8.3% |
| 2013 Q2 | 1.77 Billion USD | 4.73% |
| 2013 Q1 | 1.69 Billion USD | 4.35% |
| 2012 FY | 1.62 Billion USD | 7.15% |
| 2012 Q3 | 1.64 Billion USD | 5.85% |
| 2012 Q1 | 1.56 Billion USD | 2.86% |
| 2012 Q4 | 1.62 Billion USD | -1.27% |
| 2012 Q2 | 1.55 Billion USD | -0.32% |
| 2011 Q1 | 1.48 Billion USD | 3.76% |
| 2011 FY | 1.51 Billion USD | 6.04% |
| 2011 Q4 | 1.51 Billion USD | -8.94% |
| 2011 Q3 | 1.66 Billion USD | 5.59% |
| 2011 Q2 | 1.57 Billion USD | 6.28% |
| 2010 FY | 1.43 Billion USD | 36.15% |
| 2010 Q1 | 1.12 Billion USD | 7.15% |
| 2010 Q4 | 1.43 Billion USD | 11.6% |
| 2010 Q3 | 1.28 Billion USD | 8.01% |
| 2010 Q2 | 1.18 Billion USD | 5.41% |
| 2009 Q1 | 902.81 Million USD | 3.61% |
| 2009 FY | 1.05 Billion USD | 20.68% |
| 2009 Q4 | 1.05 Billion USD | 4.66% |
| 2009 Q3 | 1 Billion USD | 5.58% |
| 2009 Q2 | 951.67 Million USD | 5.41% |
| 2008 Q4 | 871.31 Million USD | 13.65% |
| 2008 FY | 871.31 Million USD | 48.43% |
| 2008 Q1 | 638.06 Million USD | 8.7% |
| 2008 Q2 | 679.81 Million USD | 6.54% |
| 2008 Q3 | 766.68 Million USD | 12.78% |
| 2007 Q1 | 436.26 Million USD | -8.84% |
| 2007 Q4 | 587.01 Million USD | 14.49% |
| 2007 Q2 | 471.79 Million USD | 8.14% |
| 2007 FY | 587.01 Million USD | 22.67% |
| 2007 Q3 | 512.71 Million USD | 8.67% |
| 2006 FY | 478.55 Million USD | 64.22% |
| 2006 Q4 | 478.55 Million USD | 60.71% |
| 2006 Q3 | 297.77 Million USD | -8.5% |
| 2006 Q2 | 325.43 Million USD | 6.79% |
| 2006 Q1 | 304.75 Million USD | 4.58% |
| 2005 Q1 | 216.92 Million USD | 4.71% |
| 2005 Q2 | 234.22 Million USD | 7.97% |
| 2005 Q3 | 257.17 Million USD | 9.8% |
| 2005 Q4 | 291.41 Million USD | 13.31% |
| 2005 FY | 291.41 Million USD | 40.67% |
| 2004 Q1 | 176.04 Million USD | -1.93% |
| 2004 FY | 207.15 Million USD | 15.41% |
| 2004 Q4 | 207.15 Million USD | 6.17% |
| 2004 Q3 | 195.11 Million USD | 6.47% |
| 2004 Q2 | 183.25 Million USD | 4.1% |
| 2003 Q2 | 184.66 Million USD | 1.48% |
| 2003 FY | 179.5 Million USD | -2.74% |
| 2003 Q3 | 188.08 Million USD | 1.85% |
| 2003 Q4 | 179.5 Million USD | -4.56% |
| 2003 Q1 | 181.98 Million USD | -1.4% |
| 2002 Q2 | 200.6 Million USD | -0.79% |
| 2002 Q1 | 202.19 Million USD | -4.68% |
| 2002 Q3 | 187.47 Million USD | -6.55% |
| 2002 Q4 | 184.56 Million USD | -1.55% |
| 2002 FY | 184.56 Million USD | -12.99% |
| 2001 Q4 | 212.12 Million USD | -2.73% |
| 2001 Q3 | 218.07 Million USD | -5.12% |
| 2001 FY | 212.12 Million USD | -15.37% |
| 2001 Q1 | 240.99 Million USD | -3.85% |
| 2001 Q2 | 229.84 Million USD | -4.63% |
| 2000 Q1 | 130.4 Million USD | 117.7% |
| 2000 FY | 250.64 Million USD | 318.44% |
| 2000 Q3 | 252.44 Million USD | 104.62% |
| 2000 Q4 | 250.64 Million USD | -0.71% |
| 2000 Q2 | 123.37 Million USD | -5.39% |
| 1999 Q2 | 59.9 Million USD | 236.52% |
| 1999 Q4 | 59.9 Million USD | -5.67% |
| 1999 FY | 59.9 Million USD | 220.32% |
| 1999 Q3 | 63.5 Million USD | 6.01% |
| 1999 Q1 | 17.8 Million USD | 0.0% |
| 1998 FY | 18.7 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | -381.623% |
| Alkermes plc | 2.13 Billion USD | -235.499% |
| Agenus Inc. | 313.91 Million USD | -2183.117% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | -87.134% |
| Aptorum Group Limited | 20.64 Million USD | -34623.684% |
| Ardelyx, Inc. | 297.57 Million USD | -2308.436% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | -836.187% |
| Bicycle Therapeutics plc | 595.34 Million USD | -1103.842% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -9624.295% |
| ChromaDex Corporation | 54.96 Million USD | -12939.444% |
| Chimerix, Inc. | 212.77 Million USD | -3268.363% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -25249.817% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -1525.288% |
| CRISPR Therapeutics AG | 2.22 Billion USD | -221.452% |
| Precision BioSciences, Inc. | 159.78 Million USD | -4385.515% |
| Dyadic International, Inc. | 8.21 Million USD | -87097.886% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -22480.34% |
| Fortress Biotech, Inc. | 167.52 Million USD | -4178.142% |
| Lantern Pharma Inc. | 43.64 Million USD | -16320.141% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -4342.254% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -49304.938% |
| Incyte Corporation | 6.78 Billion USD | -5.675% |
| IO Biotech, Inc. | 150.71 Million USD | -4655.238% |
| Jaguar Health, Inc. | 50.76 Million USD | -14018.551% |
| Novavax, Inc. | 1.85 Billion USD | -286.29% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -1784.035% |
| Opthea Limited | 188.79 Million USD | -3696.257% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | -760.318% |
| ContextLogic Inc. | 423 Million USD | -1594.326% |
| MiMedx Group, Inc. | 239.04 Million USD | -2898.155% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -4025.462% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -138534.71% |
| NextCure, Inc. | 129.41 Million USD | -5437.87% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -13185.015% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -19413.191% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -22088.168% |
| Vaxcyte, Inc. | 1.4 Billion USD | -409.05% |
| PDS Biotechnology Corporation | 59.39 Million USD | -11967.672% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -1018.887% |
| Pharming Group N.V. | 462.85 Million USD | -1448.436% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -18428.956% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -1040.234% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -37773.193% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -37773.193% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -4235.229% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -15725.734% |
| Acelyrin, Inc. | 742.69 Million USD | -865.006% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -108713.102% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -111831.907% |
| Summit Therapeutics Inc. | 202.94 Million USD | -3431.429% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -9536.432% |
| Senti Biosciences, Inc. | 119.48 Million USD | -5898.293% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -3038.713% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -4161.658% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -86636.052% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -150032.977% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -1427.52% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -5696.058% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -2506.665% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -1415.735% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -70825.285% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -3241.165% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -632938.292% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -1631.82% |
| Immix Biopharma, Inc. | 19.92 Million USD | -35869.598% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -1836.896% |
| MEI Pharma, Inc. | 41.37 Million USD | -17222.054% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -22016.275% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -2003.005% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -6013.884% |
| Fortress Biotech, Inc. | 167.52 Million USD | -4178.142% |
| Precigen, Inc. | 151.04 Million USD | -4645.006% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -20968.258% |
| AlloVir, Inc. | 190.79 Million USD | -3656.368% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -1803.833% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -1315.796% |
| ImmuCell Corporation | 43.8 Million USD | -16259.987% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -1003.777% |
| Onconetix, Inc. | 88.82 Million USD | -7968.997% |
| PureTech Health plc | 693.97 Million USD | -932.749% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -7236.848% |
| Elevation Oncology, Inc. | 89.09 Million USD | -7944.584% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -115459.497% |
| Seer, Inc. | 436.26 Million USD | -1542.794% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -8683.411% |
| Innoviva, Inc. | 1.24 Billion USD | -476.354% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -5312.202% |
| ESSA Pharma Inc. | 149.12 Million USD | -4706.128% |
| GlycoMimetics, Inc. | 45.31 Million USD | -15715.44% |
| GT Biopharma, Inc. | 14.1 Million USD | -50697.363% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -2227.757% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -2865.209% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -1418.731% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -14036.931% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -7427.413% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -1134658.735% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -1165.492% |
| Aptose Biosciences Inc. | 12.92 Million USD | -55361.216% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -32308.917% |
| Soligenix, Inc. | 9.79 Million USD | -73052.613% |
| Century Therapeutics, Inc. | 360.69 Million USD | -1887.019% |
| Kura Oncology, Inc. | 448.93 Million USD | -1496.445% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -2533.484% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -41339.722% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -6361.919% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -3393.524% |
| Autolus Therapeutics plc | 375.38 Million USD | -1809.26% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -2748.162% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -1917.827% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -14487.234% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -984.047% |
| GRI Bio, Inc. | 2.95 Million USD | -242356.022% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -67479.889% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -4103.149% |
| IGM Biosciences, Inc. | 423.41 Million USD | -1592.682% |
| INmune Bio, Inc. | 57 Million USD | -12473.464% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -3121.037% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -8438.114% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -27342.045% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -104023.158% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -9427.291% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -4766.968% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -4230.409% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -1038.335% |
| Verastem, Inc. | 149.71 Million USD | -4687.0% |
| Abeona Therapeutics Inc. | 64 Million USD | -11098.088% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -1299.384% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -4540.126% |
| Histogen Inc. | 19.07 Million USD | -37476.679% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -31542.141% |
| Surrozen, Inc. | 46.08 Million USD | -15453.385% |
| Organovo Holdings, Inc. | 6.34 Million USD | -112783.919% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -166240.963% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -4876.158% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -60626.995% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -9421.975% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -84027.124% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -1874.549% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -39508.946% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -1569.065% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -56728.093% |
| Apollomics, Inc. | 55.38 Million USD | -12839.86% |
| Amarin Corporation plc | 831.68 Million USD | -761.746% |
| Mesoblast Limited | 669.15 Million USD | -971.055% |
| Turnstone Biologics Corp. | 112.81 Million USD | -6252.879% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -1144.792% |
| Synaptogenix, Inc. | 31.11 Million USD | -22934.893% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -58723.047% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -1207.699% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -121948.39% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -97474.47% |
| Exelixis, Inc. | 2.94 Billion USD | -143.58% |
| Better Therapeutics, Inc. | 22.94 Million USD | -31138.286% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -1866.045% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | -808.676% |
| NLS Pharmaceutics AG | 1.84 Million USD | -388010.087% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -89727.407% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -48671.691% |
| Gritstone bio, Inc. | 177.76 Million USD | -3931.637% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -7414.154% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -40023.68% |
| Avid Bioservices, Inc. | 336.55 Million USD | -2029.506% |
| Insmed Incorporated | 1.32 Billion USD | -438.938% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -74336.469% |
| MediWound Ltd. | 66.45 Million USD | -10684.092% |
| OmniAb, Inc. | 401.98 Million USD | -1682.902% |
| Alector, Inc. | 621.82 Million USD | -1052.571% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -1898.606% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -133165.154% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -12541.995% |
| Zai Lab Limited | 1.03 Billion USD | -591.598% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -1397.95% |
| Aura Biosciences, Inc. | 255.07 Million USD | -2709.762% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | -855.563% |
| Immunic, Inc. | 54.29 Million USD | -13099.138% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -2592.094% |
| Veracyte, Inc. | 1.13 Billion USD | -529.888% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -60520.25% |
| FibroGen, Inc. | 423.52 Million USD | -1592.21% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -203913.664% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -151210.907% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -131901.64% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 37.095% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -81296.934% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -1285.051% |
| TG Therapeutics, Inc. | 329.58 Million USD | -2074.54% |
| Galecto, Inc. | 38.22 Million USD | -18648.529% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -24893.026% |
| Fortrea Holdings Inc. | 4.35 Billion USD | -64.486% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -2944.553% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -28750.334% |
| XBiotech Inc. | 227.24 Million USD | -3053.893% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -7414.154% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -4925.947% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -2406.68% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -5504.955% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -1776.183% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | -380.68% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -1864.412% |
| Vaxxinity, Inc. | 44.35 Million USD | -16058.997% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -1286.374% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -38412.937% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -2249.451% |
| NexImmune, Inc. | 8.59 Million USD | -83295.887% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -66786.355% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -41745.252% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 78.334% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -32255.007% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -1826981.182% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -4034.911% |
| Ainos, Inc. | 31.84 Million USD | -22408.147% |
| Pluri Inc. | 39.52 Million USD | -18031.91% |
| Prothena Corporation plc | 696.38 Million USD | -929.177% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -2435.95% |
| Celularity Inc. | 143.88 Million USD | -4880.923% |
| Rallybio Corporation | 115.62 Million USD | -6098.755% |
| Cue Biopharma, Inc. | 61.53 Million USD | -11547.977% |
| MeiraGTx Holdings plc | 458.16 Million USD | -1464.273% |
| Omeros Corporation | 378.26 Million USD | -1794.683% |
| Humacyte, Inc. | 128.22 Million USD | -5489.481% |
| Immunocore Holdings plc | 597 Million USD | -1100.501% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -22827.797% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -10358.193% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -583.059% |
| CalciMedica, Inc. | 12.18 Million USD | -58718.219% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -2725.547% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -4093.484% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -2204.242% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -1167.825% |
| Pulmatrix, Inc. | 33.95 Million USD | -21005.483% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -26301.68% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -4988.103% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -450.894% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -5405.072% |
| Cytokinetics, Incorporated | 824.31 Million USD | -769.448% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -33829.84% |
| Nutriband Inc. | 7.51 Million USD | -95241.934% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -8977.437% |
| Vor Biopharma Inc. | 209.82 Million USD | -3315.655% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 0.768% |
| Evogene Ltd. | 51.1 Million USD | -13925.166% |
| ProKidney Corp. | 420.55 Million USD | -1604.189% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -12970.596% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -75181.415% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -1211.724% |
| CorMedix Inc. | 82.05 Million USD | -8633.858% |
| BioLineRx Ltd. | 63.92 Million USD | -11111.576% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -1680.325% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -25314.894% |
| Atai Life Sciences N.V. | 293.47 Million USD | -2342.091% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -4293.443% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -5524.794% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -1175.206% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -7310.126% |
| MediciNova, Inc. | 66.26 Million USD | -10714.852% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -8049.134% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -160509.901% |
| GeoVax Labs, Inc. | 9.28 Million USD | -77103.823% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -1118.389% |
| Biomea Fusion, Inc. | 199.92 Million USD | -3484.808% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | -276.58% |
| Mereo BioPharma Group plc | 66.49 Million USD | -10677.606% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -1377.44% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -1069.397% |
| Absci Corporation | 234.48 Million USD | -2956.551% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -97876.76% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -2008.617% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -4241.479% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -1261.714% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -2480.908% |
| Allakos Inc. | 243.61 Million USD | -2841.997% |
| Imunon, Inc. | 21.91 Million USD | -32599.048% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -2681.206% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -1053.146% |
| BioAtla, Inc. | 119.65 Million USD | -5889.57% |
| NLS Pharmaceutics AG | 1.84 Million USD | -388010.087% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -222477.64% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -1014.902% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -7370.683% |
| XOMA Corporation | 234.3 Million USD | -2958.886% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -3139.542% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -5595.146% |
| aTyr Pharma, Inc. | 122.06 Million USD | -5771.366% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -4556.829% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -1135.113% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -1361.389% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -6387.793% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -47183.339% |
| Akari Therapeutics, Plc | 4.35 Million USD | -164469.46% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -41966.443% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -313.496% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -232294.051% |
| UroGen Pharma Ltd. | 178.31 Million USD | -3919.382% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -1422.509% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -1289589.859% |
| Orgenesis Inc. | 14.55 Million USD | -49150.962% |
| Entera Bio Ltd. | 11.76 Million USD | -60817.977% |
| GH Research PLC | 226.3 Million USD | -3067.035% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -13003.814% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -6570.948% |
| Xencor, Inc. | 952.69 Million USD | -652.289% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -91976.193% |
| Replimune Group, Inc. | 487.72 Million USD | -1369.485% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -88698.426% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -1005.268% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -232294.051% |
| Portage Biotech Inc. | 7.77 Million USD | -92032.665% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -160509.901% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -2487.878% |
| OncoCyte Corporation | 74.89 Million USD | -9469.78% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -352390.203% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -123754.193% |
| Purple Biotech Ltd. | 44.3 Million USD | -16077.599% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -20901.582% |
| scPharmaceuticals Inc. | 94.47 Million USD | -7485.813% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -39617.466% |
| HilleVax, Inc. | 344.43 Million USD | -1980.805% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -225561.209% |
| Tharimmune, Inc. | 10.94 Million USD | -65373.622% |
| Genprex, Inc. | 10.67 Million USD | -67065.908% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -1344.392% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -7346.079% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -295324.567% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -171958.613% |
| OKYO Pharma Limited | 1.54 Million USD | -464907.942% |
| Savara Inc. | 177.56 Million USD | -3936.291% |
| Curis, Inc. | 77.28 Million USD | -9173.828% |
| Daré Bioscience, Inc. | 21.28 Million USD | -33576.006% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -11107.403% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -88534.677% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -36898.606% |
| BeiGene, Ltd. | 5.8 Billion USD | -23.457% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -58795.554% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | -243.15% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -1902.229% |
| Erasca, Inc. | 395.29 Million USD | -1713.067% |
| bluebird bio, Inc. | 619.16 Million USD | -1057.534% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -165673.497% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | -4.756% |
| DBV Technologies S.A. | 182.98 Million USD | -3816.693% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -165673.497% |
| Moderna, Inc. | 18.42 Billion USD | 61.104% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -39242.373% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -61759.14% |
| Molecular Templates, Inc. | 35.38 Million USD | -20155.49% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -5083.524% |
| Travere Therapeutics, Inc. | 788.91 Million USD | -808.465% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -2259.467% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -6794.926% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -1439.215% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -2186.584% |
| MacroGenics, Inc. | 306.82 Million USD | -2235.897% |
| RenovoRx, Inc. | 1.46 Million USD | -488781.31% |
| Adicet Bio, Inc. | 207.29 Million USD | -3357.392% |
| Prime Medicine, Inc. | 193.85 Million USD | -3597.169% |
| Aditxt, Inc. | 44.57 Million USD | -15977.319% |
| Adagene Inc. | 115.72 Million USD | -6092.925% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -160804.712% |
| Quantum-Si incorporated | 298.25 Million USD | -2303.018% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | -381.831% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -92867.773% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -1940.247% |
| SciSparc Ltd. | 11.18 Million USD | -63994.08% |
| Vericel Corporation | 353.65 Million USD | -1926.54% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -58585.249% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -12495.647% |
| Generation Bio Co. | 374.75 Million USD | -1812.434% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -2714.274% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -4419.856% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -1999.512% |
| Invivyd, Inc. | 229.18 Million USD | -3027.223% |
| Relay Therapeutics, Inc. | 843.98 Million USD | -749.191% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -58794.098% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -3829.492% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -34991.069% |
| 2seventy bio, Inc. | 565.42 Million USD | -1167.54% |
| ADMA Biologics, Inc. | 329.18 Million USD | -2077.215% |
| Clene Inc. | 52.34 Million USD | -13592.898% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -12102.404% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -5417.576% |
| GeoVax Labs, Inc. | 9.28 Million USD | -77103.823% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -996.376% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -6817.209% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -5396.756% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -7246.848% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -9994.793% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -2854.818% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | -265.646% |
| Evaxion Biotech A/S | 12.88 Million USD | -55507.199% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -2743.371% |
| Verve Therapeutics, Inc. | 752.68 Million USD | -852.187% |
| Trevena, Inc. | 40.6 Million USD | -17550.536% |
| Surrozen, Inc. | 46.08 Million USD | -15453.385% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -3073.247% |
| Cingulate Inc. | 3.49 Million USD | -205173.704% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -42999.405% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -10810.336% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -61237.003% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -2569.105% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | -856.932% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -5592.975% |
| Clearmind Medicine Inc. | 4.32 Million USD | -165634.396% |
| Kronos Bio, Inc. | 213.27 Million USD | -3260.387% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -4385.43% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -83620.669% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -1844.965% |
| Statera Biopharma, Inc. | 21.16 Million USD | -33755.015% |
| ImmunityBio, Inc. | 504.45 Million USD | -1320.75% |
| Korro Bio, Inc. | 221.66 Million USD | -3133.287% |
| Kineta, Inc. | 10.28 Million USD | -69611.118% |
| BioVie Inc. | 25.2 Million USD | -28331.061% |
| Codexis, Inc. | 136.56 Million USD | -5148.204% |
| Celularity Inc. | 143.88 Million USD | -4880.923% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -1028.034% |
| Celcuity Inc. | 191.21 Million USD | -3648.051% |
| Virax Biolabs Group Limited | 5.48 Million USD | -130590.017% |
| Cibus, Inc. | 544.41 Million USD | -1216.469% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -5592.884% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -34786.098% |
| IN8bio, Inc. | 33.7 Million USD | -21161.384% |
| Kodiak Sciences Inc. | 479.37 Million USD | -1395.081% |
| Annexon, Inc. | 297.67 Million USD | -2307.667% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -4042.535% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -5113.539% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -34039.951% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -139.693% |
| Eyenovia, Inc. | 28.77 Million USD | -24803.252% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -3008.95% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -99110.963% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -11663.451% |
| Arcellx, Inc. | 825.13 Million USD | -768.588% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -8679.108% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -1450.376% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -23207.317% |
| Moolec Science SA | 24.05 Million USD | -29698.819% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -2211.004% |
| Geron Corporation | 394.07 Million USD | -1718.685% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -6946.505% |
| Royalty Pharma plc | 16.38 Billion USD | 56.25% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -1104.603% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -102361.609% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -59489.355% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -3070.397% |
| Humacyte, Inc. | 128.22 Million USD | -5489.481% |
| Structure Therapeutics Inc. | 482.01 Million USD | -1386.877% |
| 89bio, Inc. | 596.26 Million USD | -1101.974% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -2742.333% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -387305.405% |
| Genelux Corporation | 27.89 Million USD | -25594.619% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -7916.51% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -3023.842% |
| Notable Labs, Ltd. | 19.54 Million USD | -36576.731% |
| Liquidia Corporation | 120.43 Million USD | -5851.126% |
| Mustang Bio, Inc. | 17.74 Million USD | -40295.671% |
| Immunovant, Inc. | 666.71 Million USD | -974.977% |
| Quantum-Si incorporated | 298.25 Million USD | -2303.018% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -4863.262% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -13133.013% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -3982.691% |
| Acasti Pharma Inc. | 73.3 Million USD | -9677.626% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -157337.557% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -27342.045% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | -642.85% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -137994.667% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -31360.428% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -13788.727% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -3866.44% |
| PepGen Inc. | 143.05 Million USD | -4910.066% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -18653.434% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -37257.31% |
| Solid Biosciences Inc. | 164.93 Million USD | -4245.243% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -121948.39% |
| Immuneering Corporation | 102.58 Million USD | -6886.433% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -166240.963% |
| Silo Pharma, Inc. | 7.74 Million USD | -92423.49% |
| Belite Bio, Inc | 94.64 Million USD | -7472.748% |
| XOMA Corporation | 234.3 Million USD | -2958.886% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -2973.486% |
| Bionomics Limited | 27.64 Million USD | -25821.284% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -1685.483% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -6573.93% |
| uniQure N.V. | 831.68 Million USD | -761.74% |
| Cassava Sciences, Inc. | 151.66 Million USD | -4625.609% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -160804.712% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -2516.792% |
| Forte Biosciences, Inc. | 38.98 Million USD | -18286.352% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -175858.738% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -19359.151% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -99110.963% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -203913.664% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -60529.388% |
| Altimmune, Inc. | 210.64 Million USD | -3302.488% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -821.35% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -6573.93% |
| Compugen Ltd. | 121.33 Million USD | -5806.836% |
| Peak Bio, Inc. | 2.59 Million USD | -275934.455% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -4058.954% |
| Benitec Biopharma Inc. | 52.21 Million USD | -13627.255% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -1996.478% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -20510.819% |
| Zura Bio Limited | 100.84 Million USD | -7007.087% |
| PolyPid Ltd. | 15.37 Million USD | -46523.731% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -5908.249% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -20510.819% |
| Instil Bio, Inc. | 325.63 Million USD | -2100.964% |
| argenx SE | 4.54 Billion USD | -57.778% |
| Immunome, Inc. | 148.54 Million USD | -4724.963% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -4468.606% |
| Verona Pharma plc | 308.12 Million USD | -2226.012% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -8141.815% |
| Shattuck Labs, Inc. | 159.56 Million USD | -4391.615% |
| CervoMed Inc. | 9.97 Million USD | -71767.485% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -3703.01% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -62834.668% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -3894.872% |
| Moolec Science SA | 24.05 Million USD | -29698.819% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -117056.084% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -4044.106% |
| AnaptysBio, Inc. | 452.38 Million USD | -1484.256% |
| Design Therapeutics, Inc. | 289.64 Million USD | -2374.425% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -9741.401% |
| NeurAxis, Inc. | 509.49 Thousand USD | -1406578.731% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -132181.285% |
| Lumos Pharma, Inc. | 40.63 Million USD | -17536.203% |
| Achilles Therapeutics plc | 161.45 Million USD | -4338.98% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -8141.815% |
| 180 Life Sciences Corp. | 5.25 Million USD | -136168.328% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -10076.38% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -83620.669% |
| Nutriband Inc. | 7.51 Million USD | -95241.934% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -2714.053% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -3496.068% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -9304.031% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -12274.819% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -1261.15% |
| Palisade Bio, Inc. | 14.05 Million USD | -50903.416% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -3308.07% |
| Beam Therapeutics Inc. | 1.45 Billion USD | -390.987% |
| Neurogene Inc. | 222.57 Million USD | -3120.067% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -1008.377% |
| AEON Biopharma, Inc. | 6.84 Million USD | -104604.164% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -1481.993% |
| Sesen Bio, Inc. | 189.17 Million USD | -3688.576% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -2536.216% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -52168.582% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -818.433% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -2584.33% |
| Athira Pharma, Inc. | 160.24 Million USD | -4372.526% |
| Vaccinex, Inc. | 3.63 Million USD | -197283.641% |
| HCW Biologics Inc. | 28.51 Million USD | -25035.321% |
| XOMA Corporation | 234.3 Million USD | -2958.886% |
| Nektar Therapeutics | 398.03 Million USD | -1700.604% |
| Arvinas, Inc. | 1.3 Billion USD | -449.364% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -41966.443% |
| Merus N.V. | 458.49 Million USD | -1463.161% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -3406.943% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -3877.159% |
| Rezolute, Inc. | 132.73 Million USD | -5299.399% |
| Clene Inc. | 52.34 Million USD | -13592.898% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -47923.711% |
| BeyondSpring Inc. | 24.8 Million USD | -28789.874% |
| Synlogic, Inc. | 75.55 Million USD | -9386.433% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -60319.828% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -76437.804% |
| Peak Bio, Inc. | 2.59 Million USD | -275934.455% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -3999.341% |
| Krystal Biotech, Inc. | 818.35 Million USD | -775.781% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -2880.81% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -887.478% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -200253.687% |
| MannKind Corporation | 475.19 Million USD | -1408.213% |
| Ikena Oncology, Inc. | 192.09 Million USD | -3631.025% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -53489.053% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -6049.873% |
| Gossamer Bio, Inc. | 311.91 Million USD | -2197.734% |
| CohBar, Inc. | 16.36 Million USD | -43692.899% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -20282.22% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -97876.76% |
| Legend Biotech Corporation | 1.84 Billion USD | -287.697% |
| Mural Oncology plc | 301.74 Million USD | -2275.184% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -22860.115% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -126070.581% |
| Disc Medicine, Inc. | 367.99 Million USD | -1847.576% |
| Champions Oncology, Inc. | 26.13 Million USD | -27326.144% |
| REGENXBIO Inc. | 573.97 Million USD | -1148.672% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -264551.959% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -4542.26% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -59251.186% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -2007.724% |
| Vaxart, Inc. | 91.83 Million USD | -7704.639% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -11864.166% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -4731.895% |
| Cellectis S.A. | 334.27 Million USD | -2044.075% |
| Longeveron Inc. | 12.17 Million USD | -58752.028% |
| Repare Therapeutics Inc. | 253.9 Million USD | -2722.754% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | -119.538% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -3468.388% |
| Revolution Medicines, Inc. | 2.08 Billion USD | -243.15% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -440946.154% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -2480.74% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -4294.291% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -5065.629% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -27981.655% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 68.469% |
| Denali Therapeutics Inc. | 1.15 Billion USD | -521.102% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -58585.249% |
| Veru Inc. | 50.59 Million USD | -14065.172% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -15633.322% |
| Cingulate Inc. | 3.49 Million USD | -205173.704% |
| Passage Bio, Inc. | 150.54 Million USD | -4660.703% |
| Context Therapeutics Inc. | 16.06 Million USD | -44518.802% |
| Exicure, Inc. | 11.58 Million USD | -61791.192% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -1805.874% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -4333.872% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -40919.918% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -2053.902% |
| Nuvalent, Inc. | 732.38 Million USD | -878.585% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -47858.794% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -7902.993% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -50403.84% |
| OmniAb, Inc. | 401.98 Million USD | -1682.902% |
| Anew Medical, Inc. | 19.45 Million USD | -36737.054% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -26716.026% |
| Lipocine Inc. | 23 Million USD | -31059.417% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -5026.353% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -2245.491% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -8438.114% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -5796.824% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -90221.361% |
| Sage Therapeutics, Inc. | 882.27 Million USD | -712.33% |
| Ocugen, Inc. | 64.54 Million USD | -11003.537% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -5654.731% |
| Q32 Bio Inc. | 306.11 Million USD | -2241.246% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -170218.441% |
| Alumis Inc. Common Stock | 89.61 Million USD | -7897.813% |
| Equillium, Inc. | 50.53 Million USD | -14083.653% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -9431.219% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -17264.643% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -421276.803% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -27316.702% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -11021.801% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -192193.606% |
| Dominari Holdings Inc. | 57.55 Million USD | -12351.788% |
| Edesa Biotech, Inc. | 8.89 Million USD | -80514.71% |
| vTv Therapeutics Inc. | 11.01 Million USD | -64948.103% |
| Bio-Techne Corporation | 2.81 Billion USD | -154.764% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -664.792% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | -783.236% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -2481.168% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -17086.226% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -973.566% |
| Nkarta, Inc. | 378.88 Million USD | -1791.603% |
| BioCardia, Inc. | 2.98 Million USD | -239839.739% |
| Iterum Therapeutics plc | 26.25 Million USD | -27193.499% |